Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasms, Germ Cell and Embryonal × Gefitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 8 Lung Neoplasms 5 Head and Neck Neoplasms 3 Esophageal Neoplasms 3 Breast Neoplasms 3 Adenocarcinoma Of Esophagus 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Colonic Neoplasms 2 Brain Neoplasms 2 Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1 Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1 Prostatic Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Kidney Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

pembrolizumab 2 Sunitinib 2 Cisplatin 2 Brentuximab Vedotin 2 tremelimumab 1 pralsetinib 1 keyhole-limpet hemocyanin 1 durvalumab 1 Tetanus Toxoid 1 Sirolimus 1 Plicamycin 1 Pemetrexed 1 Paclitaxel 1 Genistein 1 Gemcitabine 1 Gefitinib 1 Erlotinib Hydrochloride 1 Epirubicin 1 Carboplatin 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00198159 2014-09-19

IUCRO-0021

Indiana University

Phase 2 Terminated

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡